Dermapharm Holding SE : Guidance confirmed at upper end of range – in line with expectations
>H1 revenues in line, adj. EBITDA above estimates - Dermapharm released prel. H1 2023 revenue and adj. EBITDA figures. Group’s revenues came in at € 582m (+23%) in line with ODDO BHF (€582,1m) and consensus (€580.3m), adj. EBITDA was at €168m (+13%) better than we (€ 163m) and consensus (€ 162.8m) expected. Looking at Q2 results, revenues of €263m were c. 10% above previous year’s level, while H1 2023’s adj. EBITDA of € 62.2m came some 15% below Q2 2022. This decrease...Dermapharm Holding SE. Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.